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are no planned studies comparing eFs rates with neo adjuvant trastuzumab, adjuvant trastuzumab or the combination in laBC, such a study would not only inform laBC treatment recommendations but could also in directly inform decisions in the earlystage setting where the optimal duration of trastuzumab treatment is not established.
it is now more than 20 years since the association between Her2 status and risk of relapse and death was published 9 -so why did it take 20 years to get to this stage? while the results from the noaH study were predict able (that is, trastuzumab confers bene fits in Her2-positive laBC as it did in Her2-positive early-stage and metastatic breast cancer), it none theless leaves us with more questions than answers: should trastuzumab be administered before surgery, after surgery or both? what is the optimal chemotherapy regimen for co administration? were there any biologic predictors of response or resistance to therapy? How will other promising Her2-targeted agents be incorporated into the laBC management strategy? is there a more efficient paradigm for the timely evaluation of novel, promising therapeutic inno vations? would improved drug develop ment paradigms have positively impacted the design and implementation of modern neo adjuvant studies of other Her2-targeted agents, including the tyrosine kinase inhibitor lapatinib (as in neo-allto, nsaBP B41 and CalGB-40601) and the monoclonal antibody pertuzumab (as in neosPHere)? How can we learn from our experiences so that novel Her2-targeted agents with promising activity in the metastatic setting (such as t-Dm1 and HsP90 inhibitors) are evaluated efficiently? using traditional drug development stra tegies it is difficult to fathom how we will begin to tackle the seemingly exponential growth of clinical questions. Possibly, the tradi tional model of drug development whereby drugs are moved from the lab through a series of phase i to iii studies in the metastatic setting before moving into the adjuvant setting and beyond is too labor intensive, costly, inefficient and slow. Does the answer lie in the advantages and conveniences of the laBC model? if so, will we ever be brave enough to shed the traditional study paradigms, eliminate metastatic studies altogether (at least as a neces sary step before neo adjuvant trials) and adopt a primary neoadjuvant study model? imagine if the noaH trial and the smaller neo adjuvant trastuzumab-chemotherapy study from mD anderson Cancer Center 10 had been conducted at the onset of trastuzumab development-in all likelihood the adjuvant studies would have been conducted earlier, novel Her2-targeted therapy development may have been accelerated, and biologic-correlate studies might have advanced our understanding about Her2-positive disease faster. Certainly a paradigm shift is not without its challenges and drastic change will always be met with resistance, but it must be time to seriously consider such a brave new world! targeted therapies
Importance of patient selection for EGFR TKIs in lung cancer
Ariel Lopez-Chavez and Giuseppe Giaccone platinum-based chemotherapy has been the standard first-line treatment for patients with advanced non-small-cell lung cancer for decades. however, a recent study has shown the superiority of gefitinib treatment in comparison with chemotherapy in a molecularly selected cohort of patients harboring sensitizing EGFR mutations. these results demonstrate the importance of incorporating molecular selection into the design of lung cancer trials that use egFr tyrosine kinase inhibitors. 
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However, these classifications have remained largely unchanged for years and have reached their limit in providing critical information that might influence patient outcomes and treatment selection. this is evident by the very modest improvement in the survival of patients with lung cancer in the past few decades when treated with conventional chemotherapy. molecular-profiling studies indicate that activating mutations in genes such as EGFR and more recently EML and ALK trans locations have a significant role in the develop ment and progression of nsClC, and presence of these mutations defines relatively small groups of patients who are sensitive to eGFr and alK tyrosine kinase inhibitors (tKis), respectively. other mutations, such as those in KRAS, TP53 and STK11 genes are more frequent but at this time cannot be targeted effectively for treatment. 1 the selective use of targeted therapies based on molecular profiles from individual tumor samples seems to be a more rational approach to the management of lung cancer and holds the promise of improved patient outcomes. indeed, the west Japan oncology Group (wJoG) 3405 trial by mitsudomi et al. 2 is a great example of the potentials of such an approach. in this prospective, random ized trial, the eGFr tKi gefitinib was shown to be significantly superior to conventional chemotherapy for the first-line treatment of patients with advanced nsClC harboring sensitizing EGFR mutations. in this study, mitsudomi et al. 2 compared gefitinib with cisplatin plus docetaxel in 172 chemotherapy-naïve patients who had stage iiiB/iv nsClC harboring EGFR mutations (either exon 19 deletions or l858r point mutations). this study was a randomized, open-label, phase iii trial conducted in 36 centers in Japan. initially, only patients with postoperative recurrence were eligible because it was expected that the mutation analysis was going to be easier to perform on resection material. However, because of the initial slow accrual, the protocol was amended to include patients with stage iiiB/ iv disease. in addition to the requirement of an EGFR mutation, patients were eligible if they were aged ≤75 years and had wHo performance status 0-1. Patients were randomly assigned to receive either gefitinib (250 mg/day), or docetaxel (60 mg/m 2 ) and cisplatin (80 mg/m 2 ) once every 21 days for three to six cycles. treatment continued until progression of the disease, development of unacceptable toxic effects or completion of three to six chemotherapy cycles.
overall, median progression-free survival (PFs) was 9.2 months (95% Ci 8.0-13.9) in the gefitinib group and 6.3 months (95% Ci 5.8-7.8) in the cisplatin plus docetaxel group (hazard ratio [Hr] 0.489; 95% Ci 0.336-0.710; P <0.0001). Patients treated with gefitinib had a longer PFs than patients treated with cisplatin plus doce taxel in all subgroups analyzed including females, males, nonsmokers, smokers, those with postoperative recurrence, stage iiiB/iv disease, exon 19 deletion and l858r point mutations. the objective response rate in the overall population with measurable disease was 62.1% in the gefitinib group and 32.2% in the cis platin plus docetaxel group (P <0.0001).
Prior to the wJoG trial, eGFr tKis were initially tested as second-line therapy in unselected patient populations in which the frequency of EGFR mutations had been reported to be 12-15%. the Br21 trial 3 showed the superiority of erlotinib in comparison with best supportive care, and the interest trial 4 showed that gefitinib had equivalent efficacy to second-line docetaxel in previously treated patients with advanced nsClC. it was not until the subsequent discovery that mutations in the tyrosine kinase domain are associated with dramatic and sustained responses to eGFr tKis that the potential of molecular selection was finally revealed. 5 the initial clinical trials using eGFr tKis as first-line therapies in nsClC were conducted in unselected patient populations. a phase ii study of erlotinib in chemotherapynaive patients with stage iiiB/iv nsClC showed a response rate of just 22.7% and a median time-to-progression of 3 months. 6 in addition, a pooled analysis of data from five first-line eGFr tKi trials in the advanced nsClC setting showed that patients with ≤2 clinical predictors of response (asian, female, non-smoker and adenocarcinoma histology) had a response rate of approximately 20% with a median time-to-progression of 4.4 months. 7 even with careful patient selection, the results in these earlier studies have not been as good as those reported in the wJoG trial.
2 the iPass study was initiated to compare the efficacy of gefitinib versus carboplatin plus paclitaxel in the first-line treatment of clinically selected patients (east asian, adenocarcinoma histology and no or minimal smoking history) with advanced nsClC, in which the frequency of EGFR mutations in the patient population was approximately 60%. 8 the objective response rate in the overall population was higher with gefitinib than with carboplatin plus paclitaxel (43.0% versus 32.2%, respectively; P <0.001) However, there was no difference in median PFs (5.7 months versus 5.8 months, respectively) or overall survival (18.6 months versus 17.3 months respectively). By contrast, a subset analysis showed that among patients with EGFR mutations, PFs was significantly longer in those receiving gefitinib compared with those receiving carboplatin plus paclitaxel (Hr 0.48; 95% Ci 0.36-0.64; P <0.001); the objective response rate was also greater in patients receiving gefitinib (71.2% versus 47.3%, respectively; P <0.001).
in contrast to other trials that have been conducted in unselected or clinically selected cohorts of patients (table 1), the wJoG trial shows that gefitinib results in a better response rate and PFs compared with conven tional chemotherapy in the first-line treatment of patients with advanced nsClC harboring an activating EGFR mutation.
''
Patients treated with gefitinib had a longer PFS than patients treated with cisplatin plus docetaxel… '' eGFR TKi sensitizing mutation-positive. Abbreviations: Os, overall survival; PFs, progression-free survival; RR, response rate; TKi, tyrosine kinase inhibitor; TTP, time-to-progression.
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Gefitinib is superior to chemotherapy in ■ the first-line treatment of patients with advanced nsCLC harboring an activating EGFR mutation 
